Hims & Hers Health, Inc.
Extracted from this filing and checked against the source text.
Hims & Hers Health, Inc. shareholders approved Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-11 meeting.
Proposal 2 : The ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026: For Against Abstentions 1,591,246,881 516,386 433,438 As a routine proposal under applicable rules, no broker non-votes were recorded in connection with this proposal.View on SEC.gov
Hims & Hers Health, Inc. shareholders approved Election of nine directors to serve as directors until the 2027 annual meeting of stockholders and until their respective successors are duly elected and qualified at the 2026-06-11 meeting.
Proposal 1 : The election of nine directors to serve as directors until the 2027 annual meeting of stockholders and until their respective successors are duly elected and qualified: Name For Withheld Broker Non-Votes Andrew Dudum 1,504,939,830 13,028,642 74,228,233 Kofi Amoo-Gottfried 1,517,440,666 527,806 74,228,233 Deborah Autor 1,516,370,269 1,598,203 74,228,233 Delos Cosgrove, M.D. 1,516,949,085 1,019,387 74,228,233 Anja Manuel 1,516,973,593 994,879 74,228,233 Christopher Payne 1,508,808,309 9,160,163 74,228,233 Andrea Perez 1,516,871,986 1,096,486 74,228,233 Kare Schultz 1,516,971,244 997,228 74,228,233 David Wells 1,501,758,393 16,210,079 74,228,233View on SEC.gov
Hims & Hers Health, Inc. shareholders approved Advisory approval of the Company’s executive compensation at the 2026-06-11 meeting.
Proposal 3 : Advisory approval of the Company’s executive compensation: For Against Abstentions Broker Non-Votes 1,506,477,171 11,181,420 309,881 74,228,233View on SEC.gov
1639 shareholder votes filed in the last 30 days. Browse all shareholder votes →
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.